CytoDyn Inc. (CYDY), a clinical-stage oncology company, announced on Tuesday completion of enrolment in the Phase 2 CLOVER trial for Leronlimab in combination with trifluridine and tipiracil plus bevacizumab for treating metastatic colorectal cancer (mCRC).
Leronlimab is a first-in-class monoclonal antibody (mAb) that acts by inhibition of CCR5, modulating the tumor microenvironment to effect an immune response against cancer cells.
The drug is currently being evaluated for the treatment of CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC) in the Phase 2 CLOVER open-label, randomized, two-arm, multicenter trial. With 60 patients enrolled, the study will aim to meet a primary endpoint of overall response rate (ORR), and secondary endpoints of safety, tolerability, and overall survival (OS) over a 12-month follow-up period.
The company plans to release topline data from the trial as it becomes available.
CYDY closed Tuesday at $0.37, up 2.78%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.